PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.

Abstract

Background: The advent of PD-1/L1 inhibitors has changed the landscape for patients with non-small-cell lung cancer (NSCLC). Meanwhile, the adverse events of PD-1/L1 inhibitors have been focused. Methods: The Cochrane Central Register of Controlled Trials, PubMed and Embase databases and ClinicalTrials.gov were searched from inception to February 2021. Results: 18 studies involving 11,394 patients with NSCLC were included. PD-1/L1 inhibitor monotherapy was associated (relative risk, 95% confidence interval) with an increased risk of pericardial effusion (2.72 [1.45-5.12]; p = 0.002) and cardiac tamponade (2.76 [1.15-6.62]; p = 0.023), whereas PD-1/L1 inhibitors combined with chemotherapy did not increase the risk of pericardial effusion and cardiac tamponade (3.08 [0.93-10.21]; p = 0.066 and 3.27 [0.37-28.94]; p = 0.288, respectively). Conclusion: For patients with NSCLC, treatment with PD-1/L1 inhibitor monotherapy increases the risk of pericardial effusion and cardiac tamponade, but PD-1/L1 inhibitors combined with chemotherapy do not.

• Authors: Honglin Li, Deting Han, Lei Zhang, Xiaoteng Feng, Huijie Li, Feiran Yang, Lucheng Song, Xiurong Li
• Journal: Immunotherapy (Immunotherapy) Vol. 14 Issue 7 Pg. 577-592 (05 2022) ISSN: 1750-7448 [Electronic] England
• PMID: 35373580 (Publication Type: Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, Systematic Review)

Chemical References

• B7-H1 Antigen
• Immune Checkpoint Inhibitors
• Programmed Cell Death 1 Receptor

Topics

• B7-H1 Antigen
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cardiac Tamponade (drug therapy, epidemiology)
• Humans
• Immune Checkpoint Inhibitors (adverse effects)
• Lung Neoplasms (drug therapy)
• Pericardial Effusion (drug therapy, epidemiology)
• Programmed Cell Death 1 Receptor (therapeutic use)